Chubb has launched a new insurance solution aimed at businesses operating in the life sciences sector.
The Premier Life Science package combines multiple lines of coverage – including liability, cyber protection, and professional indemnity – into a single, customisable policy structure.
This rollout marks two decades of Chubb’s dedicated life sciences underwriting capability in the Asia-Pacific region.
Premier Life Science offers consolidated access to several key types of coverage, including:
Industries eligible for coverage include pharmaceutical manufacturers, biotech developers, medtech companies, and healthcare IT service providers.
Chubb has positioned the new offering as a response to increasingly complex exposures faced by life sciences firms, including those introduced by expanding regulatory expectations and digital transformation.
The World Economic Forum’s Global Cybersecurity Outlook 2025 identified geopolitical tension, regulatory fragmentation, and workforce shortages as key drivers of cyber risk worldwide.
According to the WEF, these challenges have widened the gap in cyber resilience between larger and smaller organisations and between mature and emerging markets.
The report calls for a shift from traditional security frameworks to models that prioritise operational resilience and long-term preparedness.
Business leaders, the report noted, should view cybersecurity as a core component of strategy rather than a cost centre. It also encouraged deeper collaboration across sectors to close skills gaps and protect digital infrastructure.
Travis McIntosh, who leads Chubb’s Life Sciences division in Asia Pacific, said the launch draws on the company’s long-standing experience in the sector.
“Over the past two decades, Chubb has established itself as a leading insurance specialist in life sciences in APAC. The team has grown from a single specialist to a dedicated unit with deep insights into the industry’s unique needs and complexities. This growth has enabled us to develop insurance solutions that protect and empower businesses,” he said. “The launch of Premier Life Science is a testament to our legacy in this sector and commitment to supporting the innovative companies advancing health and science.”
Premier Life Science is now accessible in Singapore, Australia, Hong Kong, and South Korea, with additional markets expected to follow.